Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
New Technologies in Brain Tumor Diagnosis and Therapies: Basic, Clinical,...
share announcement

New Technologies in Brain Tumor Diagnosis and Therapies: Basic, Clinical, and Translational Research

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 3487

Special Issue Editor

Dr. Mingli Liu

E-Mail Website
Guest Editor
Department Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA
Interests: molecular pathways; therapeutic targets; brain tumors; cancer stem cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Brian tumors are devastating disorders of the central nervous system (CNS), with glioblastoma multiforme (GBMs) being the most malignant tumor in humans. Accumulating evidence shows that, for most brain tumors, current chemo- and radio therapies’ failures and tumor recurrence are attributed to the presence of a small population of cancer stem cells (CSC). In addition, brain tumorigenesis is also dependent on the tumor’s microenvironment, including neurons, glial cells, and the interaction between them as well as immune cells. The 2016 World Health Organization (WHO) Classification of Tumors of the CNS, for the first time, integrated molecular parameters into the diagnosis of brain tumors, which is more objective and precise and allows for improved tailoring of patient therapy. The therapeutic strategies for brain tumors are either to develop a mechanism-based combination approach to target and eradicate cancer cells and CSCs or increase stimulation of immune “cold” (immunosuppressive) brain tumors. Neural stem cell (NSC)-targeted cancer therapy has emerged as an attractive cellular strategy to treat CNS tumors. NSCs are tumor-tropic cells that display the ability to traffic into hypoxic regions of tumors, as initially described in glioma, in secondary brain metastasis, and later in several other solid tumors. Delivering anticancer reagents using NSCs can greatly enhance therapeutic distribution to brain tumor areas while sparing non-tumor tissues, thereby minimizing their toxic side effects.

This Special Issue of Cancers encompasses new research articles and timely reviews on new technologies in brain tumor diagnosis and treatment, ranging from basic to clinical and translational research.

Dr. Mingli Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain tumors
  • glioma
  • neural stem cells
  • cancer stem cells
  • neuron
  • glial cells
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 750 KiB  
Article
Predictors for the Occurrence of Seizures in Meningioma
by Johannes Naegeli, Caroline Sander, Johannes Wach, Erdem Güresir, Jürgen Meixensberger and Felix Arlt
Cancers 2024, 16(17), 3046; https://doi.org/10.3390/cancers16173046 - 31 Aug 2024
Viewed by 456
Abstract
Seizure is a common symptom of meningioma that has a major impact on patients’ quality of life. The purpose of this study was to identify predictive factors for the occurrence of preoperative and postoperative seizures. The data of patients with resection of histologically [...] Read more.
Seizure is a common symptom of meningioma that has a major impact on patients’ quality of life. The purpose of this study was to identify predictive factors for the occurrence of preoperative and postoperative seizures. The data of patients with resection of histologically confirmed meningioma at University Hospital Leipzig from 2009 to 2018 were retrospectively examined. Univariate and multivariate logistic regression analyses of different factors influencing seizure outcome were performed. The male gender was identified as an independent positive predictor for preoperative seizures (odds ratio [OR] 1.917 [95% confidence interval {CI} 1.044–3.521], p = 0.036), whereas headache (OR 0.230 [95% CI 0.091–0.582], p = 0.002) and neurological deficits (OR 0.223; [95% CI 0.121–0.410], p < 0.001) were demonstrated to be negative predictive factors. Sensorimotor deficit after surgery (OR 4.490 [95% CI 2.231–9.037], p < 0.001) was found to be a positive predictor for the occurrence of postoperative seizures. The identified predictors for the occurrence of seizures in meningioma can contribute to improving seizure treatment and patients’ quality of life. Full article
(This article belongs to the Special Issue New Technologies in Brain Tumor Diagnosis and Therapies: Basic, Clinical, and Translational Research)
►▼ Show Figures

Figure 1

Review

Jump to: Research

28 pages, 1083 KiB  
Review
Progress in Glioma Stem Cell Research
by Vanajothi Ramar, Shanchun Guo, BreAnna Hudson and Mingli Liu
Cancers 2024, 16(1), 102; https://doi.org/10.3390/cancers16010102 - 24 Dec 2023
Cited by 5 | Viewed by 2432
Abstract
Glioblastoma multiforme (GBM) represents a diverse spectrum of primary tumors notorious for their resistance to established therapeutic modalities. Despite aggressive interventions like surgery, radiation, and chemotherapy, these tumors, due to factors such as the blood–brain barrier, tumor heterogeneity, glioma stem cells (GSCs), drug [...] Read more.
Glioblastoma multiforme (GBM) represents a diverse spectrum of primary tumors notorious for their resistance to established therapeutic modalities. Despite aggressive interventions like surgery, radiation, and chemotherapy, these tumors, due to factors such as the blood–brain barrier, tumor heterogeneity, glioma stem cells (GSCs), drug efflux pumps, and DNA damage repair mechanisms, persist beyond complete isolation, resulting in dismal outcomes for glioma patients. Presently, the standard initial approach comprises surgical excision followed by concurrent chemotherapy, where temozolomide (TMZ) serves as the foremost option in managing GBM patients. Subsequent adjuvant chemotherapy follows this regimen. Emerging therapeutic approaches encompass immunotherapy, including checkpoint inhibitors, and targeted treatments, such as bevacizumab, aiming to exploit vulnerabilities within GBM cells. Nevertheless, there exists a pressing imperative to devise innovative strategies for both diagnosing and treating GBM. This review emphasizes the current knowledge of GSC biology, molecular mechanisms, and associations with various signals and/or pathways, such as the epidermal growth factor receptor, PI3K/AKT/mTOR, HGFR/c-MET, NF-κB, Wnt, Notch, and STAT3 pathways. Metabolic reprogramming in GSCs has also been reported with the prominent activation of the glycolytic pathway, comprising aldehyde dehydrogenase family genes. We also discuss potential therapeutic approaches to GSC targets and currently used inhibitors, as well as their mode of action on GSC targets. Full article
(This article belongs to the Special Issue New Technologies in Brain Tumor Diagnosis and Therapies: Basic, Clinical, and Translational Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop